116 related articles for article (PubMed ID: 26114115)
1. Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity.
Couture F; Ly K; Levesque C; Kwiatkowska A; Ait-Mohand S; Desjardins R; Guérin B; Day R
Biomed Res Int; 2015; 2015():824014. PubMed ID: 26114115
[TBL] [Abstract][Full Text] [Related]
2. Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations.
Łepek T; Kwiatkowska A; Couture F; Ly K; Desjardins R; Dory Y; Prahl A; Day R
Eur J Cell Biol; 2017 Aug; 96(5):476-485. PubMed ID: 28483279
[TBL] [Abstract][Full Text] [Related]
3. PACE4-based molecular targeting of prostate cancer using an engineered ⁶⁴Cu-radiolabeled peptide inhibitor.
Couture F; Levesque C; Dumulon-Perreault V; Ait-Mohand S; D'Anjou F; Day R; Guérin B
Neoplasia; 2014 Aug; 16(8):634-43. PubMed ID: 25220591
[TBL] [Abstract][Full Text] [Related]
4. Novel Insights into Structure-Activity Relationships of N-Terminally Modified PACE4 Inhibitors.
Kwiatkowska A; Couture F; Levesque C; Ly K; Beauchemin S; Desjardins R; Neugebauer W; Dory YL; Day R
ChemMedChem; 2016 Feb; 11(3):289-301. PubMed ID: 26751825
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation of subtilisin-like proprotein convertase PACE4 by E2F: possible role of E2F-mediated upregulation of PACE4 in tumor progression.
Yuasa K; Suzue K; Nagahama M; Matsuda Y; Tsuji A
Gene; 2007 Nov; 402(1-2):103-10. PubMed ID: 17825503
[TBL] [Abstract][Full Text] [Related]
6. Knockdown strategies for the study of proprotein convertases and proliferation in prostate cancer cells.
D'Anjou F; Couture F; Desjardins R; Day R
Methods Mol Biol; 2014; 1103():67-82. PubMed ID: 24318887
[TBL] [Abstract][Full Text] [Related]
7. Positional Scanning Identifies the Molecular Determinants of a High Affinity Multi-Leucine Inhibitor for Furin and PACE4.
Małuch I; Levesque C; Kwiatkowska A; Couture F; Ly K; Desjardins R; Neugebauer WA; Prahl A; Day R
J Med Chem; 2017 Apr; 60(7):2732-2744. PubMed ID: 28287731
[TBL] [Abstract][Full Text] [Related]
8. Role of proprotein convertases in prostate cancer progression.
Couture F; D'Anjou F; Desjardins R; Boudreau F; Day R
Neoplasia; 2012 Nov; 14(11):1032-42. PubMed ID: 23226097
[TBL] [Abstract][Full Text] [Related]
9. PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation.
Levesque C; Couture F; Kwiatkowska A; Desjardins R; Guérin B; Neugebauer WA; Day R
Oncotarget; 2015 Feb; 6(6):3680-93. PubMed ID: 25682874
[TBL] [Abstract][Full Text] [Related]
10. PACE4 regulates apoptosis in human prostate cancer cells via endoplasmic reticulum stress and mitochondrial signaling pathways.
Yao Z; Sun B; Hong Q; Yan J; Mu D; Li J; Sheng H; Guo H
Drug Des Devel Ther; 2015; 9():5911-23. PubMed ID: 26604689
[TBL] [Abstract][Full Text] [Related]
11. Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis.
Bassi DE; Zhang J; Cenna J; Litwin S; Cukierman E; Klein-Szanto AJ
Neoplasia; 2010 Jul; 12(7):516-26. PubMed ID: 20651981
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of PACE4 in prostate cancer is not dependent on E2F transcription factors.
Bakrania A; Aubé M; Desjardins R; Sabbagh R; Day R
Can J Physiol Pharmacol; 2020 Jul; 98(7):477-481. PubMed ID: 32119574
[TBL] [Abstract][Full Text] [Related]
13. PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression.
Panet F; Couture F; Kwiatkowska A; Desjardins R; Guérin B; Day R
Eur J Cell Biol; 2017 Aug; 96(5):469-475. PubMed ID: 28347547
[TBL] [Abstract][Full Text] [Related]
14. PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer.
Couture F; Sabbagh R; Kwiatkowska A; Desjardins R; Guay SP; Bouchard L; Day R
Cancer Res; 2017 Dec; 77(24):6863-6879. PubMed ID: 28993410
[TBL] [Abstract][Full Text] [Related]
15. Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue.
Dianati V; Navals P; Couture F; Desjardins R; Dame A; Kwiatkowska A; Day R; Dory YL
J Med Chem; 2018 Dec; 61(24):11250-11260. PubMed ID: 30501188
[TBL] [Abstract][Full Text] [Related]
16. Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines.
Dianati V; Kwiatkowska A; Couture F; Desjardins R; Dory YL; Day R
J Med Chem; 2018 Sep; 61(18):8457-8467. PubMed ID: 30180568
[TBL] [Abstract][Full Text] [Related]
17. Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug.
Kwiatkowska A; Couture F; Ait-Mohand S; Desjardins R; Dory YL; Guérin B; Day R
Sci Rep; 2019 Feb; 9(1):2118. PubMed ID: 30765725
[TBL] [Abstract][Full Text] [Related]
18. miR-124 exhibits antiproliferative and antiaggressive effects on prostate cancer cells through PACE4 pathway.
Kang S; Zhao Y; Hu K; Xu C; Wang L; Liu J; Yao A; Zhang H; Cao F
Prostate; 2014 Aug; 74(11):1095-106. PubMed ID: 24913567
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor.
Kwiatkowska A; Couture F; Levesque C; Ly K; Desjardins R; Beauchemin S; Prahl A; Lammek B; Neugebauer W; Dory YL; Day R
J Med Chem; 2014 Jan; 57(1):98-109. PubMed ID: 24350995
[TBL] [Abstract][Full Text] [Related]
20. PACE4 regulates apoptosis in human pancreatic cancer Panc‑1 cells via the mitochondrial signaling pathway.
Tian XF; Huang GM; Zang HL; Cao H
Mol Med Rep; 2016 Dec; 14(6):5205-5210. PubMed ID: 27779720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]